Cargando…

Engineered Toxins “Zymoxins” Are Activated by the HCV NS3 Protease by Removal of an Inhibitory Protein Domain

The synthesis of inactive enzyme precursors, also known as “zymogens,” serves as a mechanism for regulating the execution of selected catalytic activities in a desirable time and/or site. Zymogens are usually activated by proteolytic cleavage. Many viruses encode proteases that execute key proteolyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shapira, Assaf, Gal-Tanamy, Meital, Nahary, Limor, Litvak-Greenfeld, Dana, Zemel, Romy, Tur-Kaspa, Ran, Benhar, Itai
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021518/ https://www.ncbi.nlm.nih.gov/pubmed/21264238 http://dx.doi.org/10.1371/journal.pone.0015916

Ejemplares similares

Removal of Hepatitis C Virus-Infected Cells by a Zymogenized Bacterial Toxin
por: Shapira, Assaf, et al.
Publicado: (2012)

Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds
por: Vaks, Lilach, et al.
Publicado: (2018)

Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis
por: Domovitz, Tom, et al.
Publicado: (2021)

Toxin-Based Therapeutic Approaches
por: Shapira, Assaf, et al.
Publicado: (2010)

25-Hydroxyvitamin D Inhibits Hepatitis C Virus Production in Hepatocellular Carcinoma Cell Line by a Vitamin D Receptor-Independent Mechanism
por: Ravid, Amiram, et al.
Publicado: (2019)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Beneficial Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease (NAFLD) Progression in the Zebrafish Model
por: Grinberg, Lihi, et al.
Publicado: (2023)

Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
por: Soumana, Djadé I., et al.
Publicado: (2014)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships
por: Hu, Katherine, et al.
Publicado: (2020)

Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener
por: B, Uma Reddy, et al.
Publicado: (2020)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

HCV Infection Increases the Expression of ACE2 Receptor, Leading to Enhanced Entry of Both HCV and SARS-CoV-2 into Hepatocytes and a Coinfection State
por: Domovitz, Tom, et al.
Publicado: (2022)

IS COVID-19 A SEXUALLY TRANSMITTED DISEASE? A SYSTEMATIC REVIEW
por: Tur-Kaspa, Tomer, et al.
Publicado: (2020)

COVID-19 may affect male fertility but is not sexually transmitted: a systematic review
por: Tur-Kaspa, Ilan, et al.
Publicado: (2021)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

Antibody-Mediated Inhibition of Insulin-Degrading Enzyme Improves Insulin Activity in a Diabetic Mouse Model
por: Fursht, Ofir, et al.
Publicado: (2022)

1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease
por: Omar, Abdelsattar M., et al.
Publicado: (2020)

Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease
por: Wadood, Abdul, et al.
Publicado: (2013)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy
por: Dietz, Julia, et al.
Publicado: (2016)

The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease
por: Khan, Mahim, et al.
Publicado: (2022)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region
por: Hamad, Hamzah A., et al.
Publicado: (2016)

HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor
por: Sakata, Kotaro, et al.
Publicado: (2013)

Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity
por: Jittavisutthikul, Surasak, et al.
Publicado: (2016)

Treatment of HCV NS3/4a Protease Inhibitor Experienced Patients with Sofosbuvir Containing Regimens in an Outpatient Clinic
por: Gilroy, Shelley, et al.
Publicado: (2017)

Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients
por: Khan, Hafeez Ullah, et al.
Publicado: (2020)

Molecular screening of phytochemicals from Amelanchier Alnifolia against HCV NS3 protease/helicase using computational docking techniques
por: Khan, Mahim, et al.
Publicado: (2013)

A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach
por: Riaz, Muhammad, et al.
Publicado: (2023)

Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors
por: Granot-Matok, Yasmin, et al.
Publicado: (2023)

Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease
por: Kumar, Ankur, et al.
Publicado: (2018)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Allosteric Inhibitors of Zika Virus NS2B-NS3 Protease Targeting Protease in “Super-Open” Conformation
por: Meewan, Ittipat, et al.
Publicado: (2023)

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment
por: Sullivan, James C, et al.
Publicado: (2012)

Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity
por: Yao, Min, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f1eudoeo4inovhuv11u3ijdffs